E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 6/6/2006 in the Prospect News Biotech Daily and Prospect News Convertibles Daily.

Millipore's $550 million of 20-year convertibles talked 3.25%-3.75%, up 37.5%-42.5%, to price Tuesday

By Kenneth Lim

Boston, June 6 - Millipore Corp. on Tuesday offered $550 million of 20-year convertible senior unsecured notes, talked at a coupon of 3.25% to 3.75% and an initial conversion premium of 37.5% to 42.5%.

Pricing was expected Tuesday after the market closed. The notes were offered at par.

There is a greenshoe option for a further $82.5 million.

UBS Investment Bank and Goldman Sachs were the bookrunners of the Rule 144A offering.

The notes are non-callable for the first 5.5 years, until Dec. 1, 2011. There are puts on Dec. 1, 2011, and in years 10 and 15. If a planned merger between Millipore and Serologicals Corp. does not go through, Millipore may redeem the notes before Oct. 10, 2006.

There is contingent conversion at 120% of the conversion price and contingent payment at 120% of the principal.

There is full dividend protection and a change of control put with a premium make-whole feature.

The notes are expected to be rated Ba2 by Moody's Investors Service and BB- by Standard and Poor's.

Millipore said it will use the proceeds of the deal to pay part of the consideration in its merger with Serologicals, which was announced in April. Any remaining proceeds will be used as working capital.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.